APUS

1.6008.05%
EC

Erik C. Emerson

CEO & Director

Mr. Erik C. Emerson is CEO & Director of Lokahi Therapeutics Inc. Mr. Emerson is Chief Executive Officer & Director of GlucoTrack, Inc. from July 14, 2026. Mr. Emerson was appointed Chief Executive Officer of Lokahi Therapeutics Inc. in December 2025. He was a Partner at Pharmacense Consulting from May 2020 to October 2023. Mr. Emerson was President of Apimeds Pharmaceuticals US, Inc. Mr. Emerson was the Chief Executive Officer of Apimeds Pharmaceuticals US, Inc., since September 2023 & served as its Director since 2024. He served as Chief Financial Officer of Apimeds Pharmaceuticals US, Inc until October 2024. He had been Chief Commercial Officer at Oragenics, Inc. since 2024 until 2024. He also serves as an advisor to Odyssey Neuropharma, Inc. where he has served since August 2022. He was the Chief Commercial Officer at Odyssey Health, Inc. since November 2022. Mr. Emerson was the Chief Commercial Officer for Mezzion Pharmaceuticals. He was Chief Commercial Officer at Adhera Therapeutics, Inc., formerly Marina Biotech, Inc. since June 22, 2017 until January 15, 2019. Prior to that Mr. Emerson served as the Executive Chairman and Chief Executive Officer of BioMarisLLC from July 2017 to November 2019. He serves as Member of Advisory Board at NuGen Medical Devices Inc. since October 2022. Mr. Emerson served as the President and Chief Executive Officer of Symplmed Pharmaceuticals & Technologies from July 2013 to May 2018. He had founded Symplmed Pharmaceuticals in 2013. He had led Symplmed to the submission, approval and commercial launch of Prestalia® and to the eventual sale of such assets to Marina Biotech in June 2017.Prior to founding Symplmed, From May 2010 to July 2013, he served as the Senior Director of Commercial Development, Xoma Ltd. Mr. Emerson served as the Head of Commercial Development at XOMA from 2010 to 2013 and Director of Marketing at Gilead Sciences from May 2007 to May 2010. Mr. Emerson began his career in sales, sales training and marketing with King Pharmaceuticals from September 2001 to May 2007. He served as a Director of Adhera Therapeutics, Inc. (formerly, Marina Biotech, Inc.) since April 27, 2018 until February 2020. Mr. Emerson graduated from the University of Oregon with a Bachelor of Science in Political Science with a specialization in Administration and Organization in 1993.

Positions